Buradasınız

Anasayfa » Content

PHARMACOVIGILANCE AND ITS INDIAN PERSPECTIVE

Journal Name:

  • Advance Research in Pharmaceuticals and Biologicals

Publication Year:

  • 2014

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Bookmark/Search this post with
Abstract (Original Language): 
With massive expansion of healthcare as well as drug research and development activity in a populous developing nation, pharmacovigilance is the code word for quality and safety of the endeavors. A review of basic understanding and executionery tasks is attempted, drawing upon the contemporary national scenario. In the past, India’s regulatory agencies and Drug Company based their safety assessments on experiences derived from long term drug use in the western market and there was no urgency for the government to establish a strong Pharmacovigilance system of its own. But in recent years(after 2005) DCGI office significantly involve in set up of ADR monitoring centers throughout the country with help of Ministry of Health & Family Welfare Govt.of India and World health organization (WHO) Uppsala.
FULL TEXT (PDF): 
PDF icon arastirmax-pharmacovigilance-and-its-indian-perspective.pdf
  • 3
710
715
  • Turkish

REFERENCES

References: 

1. The Importance of Pharmacovigilance, WHO 2002.
2. WHO Technical Report No 498, 1972.
3. The importance of pharmacovigilance, safety
monitoring of medical products, geneva, World
Health Organization, 2002.
4. R. Mann, E. Andrews, eds, Pharmacovigilance,
Chichester, Wiley & Sons, 2002.
5. Safety monitoring of medical products WHO
Guidelines for setting up and running a
pharmacovigilance centre, stora Target 3, Uppsala,
Sweden, The Uppsala Monitoring Centre, 2000.
6. S. Shaker. PEM in the UK and Coulter D. PEM in
New Zealand in Mann R. Andrews E. eds.
Pharmacovigilance, Chichester, Wiley & Sons, 333-
362, (2002).
7. P. Biswas, A. K. Biswas. Setting standards for
proactive pharmacovigilance in India: The way
forward, Indian J Pharmacol 39: 124-128 (2007).
8. S. Prakash. Pharmacovigilance in India, Indian J
Pharmacol 39: 123 (2007).
9. S. K. Gupta. Textbook of PHARMACOVIGILANCE, 2nd
ed. 2001, pp. 39, 40,41.
Dinesh et al., ARPB, 2014; Vol 4 (III) ISSN 2250-0774
(REVIEW ARTICLE)
715 | P a g e w w w . a r p b . i n f o
10. S. I. Haider, K. Johnell, G. R. Weitoft, et. al. The
influence of educational level on polypharmacy and
inappropriate drug use: a register-based study of
more than 600,000 older people, Journal of the
American Geriatrics Society 57(1): 62–69 (2009).
11. S. I. Haider, K. Johnell, M. Thorslund, et. al. Trends in
polypharmacy and potential drug- drug interactions
across educational groups in elderly patients in
Sweden for the period 1992 – 2002, International
Journal of Clinical Pharmacology and Therapeutics
45 (12): 643–653 (2007).
12. S. P. Fisher-Hoch. Lessons from nosocomial viral
haemorrhagic fever outbreaks, Br. Med. Bull., 73-74:
123–137 (2005).
13. S. N. Weingart, A. N. Ship, M. D. Aronson.
Confidential clinician-reported surveillance of
adverse events among medical inpatients, J Gen
Intern Med, 15 (7): 470–477 (2000).
14. Letter: Tranquilizers causing aggression, British
Medical Journal 1(5952): 266 (1975).
15. Chlorpromazine- Adverse Effects- Behavioral
Reactions.
16. M. H. Teicher, C. Glod, J. O. Cole. Emergence of
intense suicidal preoccupation during fluoxetine
treatment, Am J Psychiatry 147 (2): 207–210
(1990).
17. J. P. Ioannidis, J. Lau. Completeness of safety
reporting in randomized trials: an evaluation of 7
medical areas, JAMA 285(4): 437–443 (2001).
18. R. Chou, M. Helfand. Challenges in systematic
reviews that assess treatment harms, Ann Intern
Med, 142(12 Pt 2): 1090–2000 (2005).
19. J. P. Ioannidis, S. J. Evans, P. C. Gøtzsche, et. al. Better
reporting of harms in randomized trials: an
extension of the CONSORT statement, Ann Intern
Med, 141(10): 781–788 (2004).
20. The Uppsala monitoring system, WHO Collaborating
Centre for International Drug Monitoring World
Health Organization, 2002, 28-34.
21. S. Gunasakaran, K. R. Satheesh. A Practical Guide on
Pharmacovigilance for Beginners, First Edition.
22. The Safety of Medicines in Public Health
Programmes Pharmacovigilance: an essential tool
World Health Organization, 33-48.
23. Z. Syed, A. Rahat, G. Varun, U. Misbah.
Pharmacoenvironmentology– a component of
pharmacovigilance, Environmental Health July,
2007.
24. S. Surendra, A. Dang, P. Rataboli. Pharmacovigilance
and Pharmaco epidemiology, Indian J Pharm Sci.
July 2010.
25. P. RaviShankar, P. Subish, P. Mishra, A. K. Dubey.
Teaching Pharmacovigilance to Medical students
and doctors, Educational Forum, July 2010.
26. WHO guidelines on safety monitoring of herbal
medicines in pharmacovigilance systems, World
Health Organization, Geneva, 2004.
27. Protocol for National pharmacovigilance program,
CDSCO, Ministry of Health and family welfare,
government of India, November 2004.
28. M. D. Nair Pharmacovigilance: The need for a formal
System in India, available from
http://www.pharmabij.com.
29. G. Duff, M. Kendall, J. Raine, et. al. Henderson
Current problems in pharmacovigilance
commission on human medicines, MHRA, UK, 31: 1-
12 (2006).
30. MHRA/CSM Current Problems in
Pharmacovigilance, 30: 1-2 (2004).
31. MCA/CSM Current Problems in Pharmacovigilance,
24: 5 (1998).
32. MCA/CSM Current Problems in Pharmacovigilance,
28: 7 (2002).
33. MCA/CSM Current Problems in Pharmacovigilance,
29: 5 (2003).
34. BTS/SIGN. Management of Asthma, Thorax, 54: 1-
94 (2003).
35. Paradoxical Reactions to Benzodiazepines.
36. D. F. Chang & J. R. Campbell. J Cataract Refract Surg
31: 664-673 (2005).
37. M. J. Krantz et al. Ann. Intern. Med., 137: 501-504
(2002).
38. R. Grant, N. Wilkinson. Engl J Med, 352: 2211-2221,
(2005).
39. B. Meessen, Z. Zhenzhong, W. Van Damme, et. al.
Iatrogenic poverty, Tropical Medicine &
International Health, 8 (7): 581–584 (2007).
40. A. Wayne, N. Ray. Engl J Med 351: 1089-1096
(2004).
41. K. Hawton et al. British Medical Journal 326: 1006-
1008 (2003).

Thank you for copying data from http://www.arastirmax.com